GlassScriptPhysician profile
Jang S Mun
NPI 1164424578
$7,023.99
in general payments reported to CMS, 2019-2025
32 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.88 · 2020: $53.69 · 2021: $1,546 · 2022: $1,049 · 2023: $1,320 · 2024: $1,652 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,290.72 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,215.66 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,024.63 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $923.17 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $514.17 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.70 | 2019-2025 | Xifaxan |
| Amgen INC. | $437.53 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $298.97 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $291.68 | 2023-2025 | |
| Pfizer INC. | $253.74 | 2020-2025 | |
| Dexcom, INC. | $252.38 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $207.26 | 2021-2024 | |
| Exact Sciences Corporation | $166.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ibsa Pharma INC. | $116.26 | 2023-2024 | Tirosint, Licart, Licart |
| Merck Sharp & Dohme LLC | $100.94 | 2022-2025 | Januvia, Steglatro, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.07 | 2019-2023 | Jardiance, Synjardy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $79.01 | 2022-2023 | |
| Astellas Pharma US INC | $75.03 | 2023-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $68.35 | 2021-2022 | |
| Glaxosmithkline, LLC. | $65.20 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $61.18 | 2021-2023 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $54.13 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $49.30 | 2022 | |
| Aimmune Therapeutics, INC. | $45.25 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.62 | 2021-2022 | |
| Viiv Healthcare Company | $24.56 | 2024 | Cabenuva |
| Phathom Pharmaceuticals, INC. | $23.30 | 2024 | Voquezna |
| Medtronic USA, INC. | $21.91 | 2020 | |
| Intra-Sana Laboratories | $17.62 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Lifescan, INC. | $17.28 | 2022 | |
| Genentech USA, INC. | $14.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jang Mun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.